Moderna Gets Canada Approval for Updated Covid-19 Vaccine
By Sabela Ojea
Moderna said that the Canadian government has approved its updated Covid-19 Spikevax for individuals aged six months and older.
The biotechnology company on Tuesday said that Health Canada authorized the vaccine targeting the KP.2 Covid-19 variant of Sars-Cov-2.
Moderna will begin delivery of updated doses to the Public Health Agency of Canada, ensuring supply is available in time for provincial and territorial vaccination campaigns, the company said.
The authorization comes shortly after the company said that it's reducing its dependence on Covid-19 vaccines. Moderna is cutting $1.1 billion in annual research and development expenses, the company said last week.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 17, 2024 11:41 ET (15:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States